Article: Yifan Pharma’s unit, eyeing US$5.5 billion post-chemotherapy treatment market dominated by Amgen, considers IPO in 2021

Article Details

Impact Score

5 / 10

AI Summary (Processed Content)

Yifan Pharmaceutical's subsidiary Evive is considering a 2021 IPO as it develops a drug candidate, F-627, targeting a major post-chemotherapy treatment market. Its lead candidate has shown promising Phase III trial results and aims to become the first novel biological drug from a Chinese company approved for sale in the US.

The drug is positioned as a competitor to Amgen's established product Neulasta, seeking to capture a share of its multi-billion dollar market. Evive's leadership expresses confidence in their lead, noting they are ahead of potential Chinese competitors in the clinical trial process.

The main topics covered are a potential IPO, clinical drug development and competition in the pharmaceutical market, and a strategic investment by a parent company.

Original URL

https://www.scmp.com/business/companies/article/3102007/yifan-pharmas-unit-eyes-us55-billion-post-chemotherapy-treatment?utm_source=rss_feed

Source Feed

Science & Research - South China Morning Post

Published Date

2020-09-18 01:50

Fetched Date

2026-03-04 14:32

Processed Date

2026-03-04 15:12

Embedding Status

Present

Cluster ID

Not Clustered

Raw Extracted Content

Yifan Pharma’s unit, eyeing US$5.5 billion post-chemotherapy treatment market dominated by Amgen, considers IPO in 2021
- Evive’s F-627 candidate has shown promising results after several phase three clinical trials, CEO Liu Jubo says
- Amgen’s second best-seller Neulasta, whose patent expired five years ago, generated US$3.2 billion of sales in 2019
In the process, the innovative drugs developer is hoping to become the first Chinese company to win regulatory approval to sell a novel biological drug in the US market, chief executive Liu Jubo said in an interview.
Biological drugs, also known as large molecule drugs, are derived from living organisms. Evive has so far conducted 10 clinical trials on 1,200 breast cancer patients in China, Europe and the US, showing its F-627 candidate drug to be “at least as efficacious and safe” as Amgen’s Neulasta.
“For the biological sector, we are pretty confident [on this candidate],” Liu said. “No other drug has completed phase three trials so far, we do not see a close catch-up player from China that will do the same thing in the near future.”
Hangzhou-based Yifan, one of the world’s largest vitamin B5 makers, paid 1 billion yuan (US$147.8 million) for a 62.3 per cent stake in Evive in 2016, a Singapore-based company founded by mainland Chinese scientists.